2,7-二氯苯并[d]噁唑 | 86691-34-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 中文名称: 2,7-二氯苯并[d]噁唑
• 英文名称: 2,7-Dichloro-benzooxazole
• 英文别名: 2,7-Dichlorobenzoxazole；2,7-dichloro-1,3-benzoxazole
• CAS: 86691-34-1
• 化学式: C₇H₃Cl₂NO
• 分子量: 188.013
• InChiKey: QGAKWVONFSNHPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,7-二氯苯并[d]噁唑 在 胆碱 、 一水合肼 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 5.75h， 生成 3-[1-(7-chloro-2-benzoxazolyl)hydrazino]propanenitrile
  参考文献：
  名称：

  3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives: inhibitors of immune complex induced inflammation

  摘要：

  3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives were evaluated in the dermal and pleural reverse passive Arthus reactions in the rat. In the pleural test these compounds were effective in reducing exudate volume and accumulation of white blood cells. This pattern of activity was similar to that of hydrocortisone and different from that of indomethacin. The structural requirements for inhibiting the Arthus reactions were studied by systematic chemical modification of 1. These structure-activity relationship studies revealed that nitrogen 1' of the hydrazino group is essential for activity and must be electron rich, whereas chemical modifications of other sites of 1 had only a modest effect on activity.

  DOI：

  10.1021/jm00117a010
• 作为产物：
  描述：

  7-氯-2-巯基苯并噁唑 在 五氯化磷 、 三氯氧磷 作用下， 生成 2,7-二氯苯并[d]噁唑
  参考文献：
  名称：

  Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: Heterocyclic P3

  摘要：

  A series of N-alpha-2-benzoxazolyl-alpha-amino acid-(arylaminoethyl)amides were identified as potent, selective, and noncovalent inhibitors of cathepsin S. Structure-activity relationships including strategies for modulating the selectivities among cathepsins S, K, and L, and in vivo pharmacokinetics are discussed. A X-ray structure of compound 3 bound to the active site of cathepsin S is also reported. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.095

文献信息

• [EN] ANTIBIOTIC COMPOUNDS<br/>[FR] COMPOSÉS ANTIBIOTIQUES
  申请人：DISCUVA LTD

  公开号：WO2018037223A1

  公开（公告）日：2018-03-01

  The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.

  本发明涉及公式（I）的抗生素化合物，含有这些化合物的组合物，以及使用这些化合物治疗细菌性疾病和感染的方法。这些化合物在治疗革兰氏阳性和/或革兰氏阴性细菌引起的感染和疾病方面具有应用，特别是在治疗由淋病奈瑟菌引起的感染和疾病方面。
• [EN] CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS<br/>[FR] CYANOGUANIDINES ET LEUR UTILISATION COMME AGENTS ANTIVIRAUX
  申请人：ABBVIE INC

  公开号：WO2014005129A1

  公开（公告）日：2014-01-03

  This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

  这份披露涉及：(a) 抑制RSV感染和/或复制的化合物及其盐，等等；(b) 用于制备这些化合物和盐的中间体；(c) 包含这些化合物和盐的组合物；(d) 制备这些中间体、化合物、盐和组合物的方法；(e) 使用这些化合物、盐和组合物的方法；以及(f) 包含这些化合物、盐和组合物的试剂盒。
• [EN] DIARYLAMINE-SUBSTITUTED QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS<br/>[FR] QUINOLONES SUBSTITUÉES PAR DIARYLAMINE UTILES COMME INHIBITEURS DE L'OXYDE NITRIQUE SYNTHASE INDUCTIBLE.
  申请人：KALYPSYS INC

  公开号：WO2009029617A1

  公开（公告）日：2009-03-05

  Novel diarylamine-substituted quinolone compounds and pharmaceutical compositions, certain of which have been found to inhibit inducible NOS synthase have been discovered, together with methods of synthesizing and using the compounds including methods for the treatment of iNOS-mediated diseases in a patient by administering the compounds.

  已发现新的含有二芳胺基取代喹诺酮化合物和药物组合物，其中一些已被发现能抑制诱导型NOS合成酶，还包括合成和使用这些化合物的方法，包括通过给患者施用这些化合物治疗iNOS介导的疾病的方法。
• 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
  申请人：DUK SAN NEOLUX CO., LTD. 덕산네오룩스 주식회사(120150011099) Corp. No ▼ 161511-0176036BRN ▼312-86-74729

  公开号：KR20210123527A

  公开（公告）日：2021-10-14

  본 발명은 화학식 1로 표시되는 화합물과, 제 1전극, 제 2전극 및 상기 제 1전극과 상기 제 2전극 사이의 유기물층을 포함하는 유기전기소자, 및 상기 유기전기소자를 포함하는 전자장치를 제공한다. 상기 유기물층에 화학식 1로 표시되는 화합물을 포함함으로써, 유기전기소자의 구동전압을 낮출 수 있고 발광 효율 및 수명을 향상시킬 수 있다.

  本发明提供了一种化学式为1的化合物，第一电极，第二电极以及包含有机物层的有机电子器件，以及包括该有机电子器件的电子装置。通过在有机物层中包含化学式为1的化合物，可以降低有机电子器件的驱动电压，并提高发光效率和寿命。
• [1-(2-Benzoxazolyl)hydrazino]alkyl nitrile derivatives
  申请人：Abbott Laboratories

  公开号：US04476137A1

  公开（公告）日：1984-10-09

  Described are compounds of the formula ##STR1## wherein R is hydrogen or loweralkyl, X, Y and W independently of one another denote hydrogen, halogen, loweralkyl, nitro, amino, amido, loweralkoxy, hydroxy, nitrile, methylsulfone, methylsulfoxide, methylmercapto, or trifluoromethyl; Z is oxygen, sulfur or --CH.sub.2 ; n and m are each an integer from 0 to 6 inclusive, or pharmaceutically acceptable salts thereof. The compounds are effective as anti-inflammatory agents.

  描述了具有以下式子的化合物：##STR1## 其中R是氢或低碳基，X，Y和W分别独立地表示氢，卤素，低碳基，硝基，氨基，酰胺基，低碳氧基，羟基，腈基，甲基磺酰基，甲基亚磺酰基，甲基硫醇基或三氟甲基；Z是氧，硫或--CH.sub.2; n和m分别为0到6之间的整数，或其药学上可接受的盐。该化合物对于抗炎症具有有效性。